摘要
目的:探讨微小RNA-141(miR-141)在卵巢癌患者组织和血清中的表达情况并初步探讨其作为肿瘤标记物早期诊断上皮性卵巢癌的可行性。方法:采用实时荧光定量逆转录聚合酶链反应(real-time RT-PCR)检测16例上皮性卵巢癌患者和4例正常人卵巢组织及血清标本中miR-141的表达;检测4例良性卵巢肿瘤血清中miR-141的表达。结果:miR-141在卵巢癌患者组织中相对表达量分别为(72.846±76.671)显著高于正常人(2.869±3.201)(P<0.05);miR-141在卵巢癌患者血清中相对表达量(31.581±52.885)显著高于良性卵巢肿瘤患者(0.668±1.196)和正常人(1.690±1.697)(P<0.05),后两组间表达无差异(P>0.05);miR-141表达随卵巢癌临床分期的进展呈上升趋势(P<0.01),在无淋巴结转移组明显高于有淋巴结转移组(P<0.05),与组织分级和CA125的升高无关(P>0.05)。在组织中miR-141表达水平与上皮性卵巢癌临床病理特征均未见明显差异(P>0.05)。结论:miR-141可能在上皮性卵巢癌的发生发展中发挥癌基因的作用;miR-141用于检测上皮性卵巢癌敏感性和特异度较高,有望成为上皮性卵巢癌早期诊断的新指标。
Objective： To investigate the expression of microRNA-141 （miR-141）in epithelial ovarian cancer samples anti to investigate the possibility of serum miR-141 used as biomarker for epithelial ovarian cancer. Methods： The expression of miR-141 in tissues and serum from 16 cases of epithelial ovarian cancer and 4 cases of normal persons and in serum from 4 cases of benign epithelial ovarian tumor was detected by real-time RT-PCR. Results： The expression of miR-141 in epithelial ovarian cancer tissues was significantly higher than those in normal persons （P 〈0.05）. The expression of miR-141 in epithelial ovarian cancer serum was significantly higher than those in benign epithelial ovarian tumor and normal persons （P〈0.05）, but there was no difference between the latter two groups. The expression of miR-141 increased with the progression of the clinical stages （P 〈0.01）, but it had not correlation with histological grading and the increasing of CA 125 （P 〉 0.05）. There was no difference for miR-141 expression with clinicpathologic features in tissues of patient of epithelial ovarian cancer （P 〉0.05）. Conclusion： MiR-141 might play a role as an oncogene in the occurrence and development of ovarian epithelial carcinoma. MiR-141 has higher sensibility and specificity, and it is expected to become a new target of early diagnosis of ovarian cancer.
出处
《现代生物医学进展》
CAS
2011年第13期2511-2515,2466,共6页
Progress in Modern Biomedicine
